Olaris, Inc. to present novel myOLARIS™-KTdx assay detecting graft status in kidney transplant recipients at American Transplant Congress 2022 Meeting

Share Article

Novel urinary metabolite-based signature differentiates rejection from PVAN infection, a complication associated with over-immunosuppression, in renal transplant patients

The myOLARIS-KTdx metabolite signature represents a non-invasive urine test that aligns with the pathology of a biopsy.

Olaris, Inc., a precision medicine company leveraging metabolomics and machine learning for the discovery and development of its myOLARIS™ diagnostics products, which aim to optimize treatments and outcomes for individual patients, is pleased to announce that the company’s study on the application of the myOLARIS-KTdx kidney transplant graft status score to transplant recipients has been selected for a poster presentation on June 6th at the upcoming American Transplant Congress (ATC) 2022 Annual Meeting, to be held June 4th-8th in Boston, Massachusetts.

As a follow-up to the company’s presentation in May 2022 at the International Transplant Science (ITS) meeting, the ATC 2022 presentation will describe the continuation of a multi-year collaboration between Olaris and Dr. Dirk Kuypers, Professor of Medicine and Chair of the Laboratory of Nephrology at the University of Leuven, to identify a biomarker signature for over-immunosuppression in kidney transplant recipients. Olaris’ researchers expanded the study to 115 kidney transplant recipients, with longitudinal samples including 371 urine samples. They applied the urine metabolite-based score to patients with different clinical statuses at 90 days through 2 years post-transplant. The myOLARIS-KTdx kidney transplant status score was highly accurate at distinguishing patients who experienced immune-mediated graft rejection from those experiencing polyomavirus-associated nephropathy (PVAN), a specific complication of over-immunosuppression that occurs in 10% of patients following kidney transplantation and leads to graft loss in more than 50% of cases. Further, myOLARIS-KTdx identified patients that retained stable graft function for 2 years with no infection or rejection events. The score also distinguished patients at risk of later PVAN development. The results of the study establish a non-invasive signature for potential use in monitoring kidney transplant status and add novel insight to the appropriate balance of immunosuppressant treatment for kidney transplant patients.

“One of the greatest unmet clinical needs in kidney transplant is the ability to find the appropriate level of immunosuppressant for an individual patient. Too little or too much of the drug can have drastic consequences for a patient, and it’s challenging to differentiate under-immunosuppression from over-immunosuppression based on symptoms alone. The myOLARIS-KTdx metabolite signature represents a non-invasive urine test that aligns with the pathology of a biopsy. This could improve outcomes and patient experience and allow early intervention to change the course of clinical management to prevent graft loss,” said Dr. Elizabeth O’Day, CEO and Founder of Olaris.

For more information on the ATC meeting or to view the Olaris presentation during the conference, visit https://atcmeeting.org/. The presentation will be made available on Olaris’ website at http://www.myolaris.com/news following the conference.

About Olaris
Olaris is on a mission to revolutionize how diseases are diagnosed and treated. By leveraging our CEREBRO platform (Comprehensive Early Responsive Evaluation of Biomarkers Related to Outcomes), which combines metabolomics and machine learning, we harness the power of the body’s own communication system to discover and develop our pipeline of myOLARIS™ precision diagnostics. To learn more, visit https://www.myolaris.com/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Laura Housman
Follow >
Olaris, Inc
Like >